Visit for more related articles at Journal of Pharmacogenomics & Pharmacoproteomics In today’s day and age, various drug delivery systems have evolved along with the development and research of varied chemotherapeutic agents to ensure safer delivery of these agents to achieve optimal clinically efficacious response.
Currently used anticancer drugs suffer from a myriad of problems such as extremely low aqueous solubility, lack of stability, nonspecific drug accumulation, which eventually leads to toxicity issues.
Biological targets, whether it be cell surface markers or tumor vasculature or the extracellular matrix surrounding the tumor microenvironment always pose monumental challenges.
Liposomal-based nanocarriers are known to be prone to extreme challenges that are encountered in their development and overall stability.Polyethylene Glycol (PEG) has been reported to increase the circulation times by affording them protection from opsonization . Call it the algorithm method: Working with data crunchers at dating sites, we put together 25 tips for writing the perfect profile. The Halfan culture flourished along the Nile Valley of Egypt and Nubia between 18,000 and 15,000 BC, though one Halfan site dates to.Free drugs are known to diffuse non- specifically; however, nanoparticles accumulate at the specific target site with the aforementioned enhanced permeability and retention effect.
With the aid of optimized targeting ligands on their surface, nanoparticles will be able to deliver the payload at the tumor site and even reduce its distribution to the peripheral tissues.
Other approved products include Abraxane (Albumin bound Paclitaxel) used to treat metastatic breast cancer  and Marqibo (Liposomal Vincristine) used to treat acute lymphoblastic leukemia .
Other approved products include Genexol-PM (PEG-L-asparginase; Enzon) which was approved by FDA in 2006 for Acute Lymphoblastic Leukemia.
Additionally, low bioavailability along with organ toxicity causes a major limiting factor for the maximum tolerated dose.
These combinations of drug delivery systems along with the chemotherapeutic agents have led to the alleviation of multiple indications in various cancers, thus leading to a more clinically enhanced response, as compared to the chemotherapeutic agents alone .
Till date, not less than 12 drug-polymer conjugates have entered Phase I and II clinical trials for targeting blood vessels in tumors.